Thrombi Formed in a Chandler Loop Mimic Human Arterial Thrombi in Structure and PAI-1 Content and Distribution

Summary

We have previously shown that whole blood clots prepared under static conditions are a poor model for human thrombi formed in vivo. The most striking contrast is in the PAI-1 content, some 100 times lower in static clots than in human thrombi. This study aimed to evaluate thrombi formed in an artificial circulation (Chandler loop) using whole blood augmented with platelets. Citrated blood was recalcified and placed in tubing, which was sealed to form a closed loop and circulated. Immunohistochemical staining revealed morphology very similar to human thrombi formed in vivo, comprising dense platelet-rich heads and fibrin-rich tails. Strong positive staining for PAI-1 was observed in fibrin-rich areas of both the head and the tail. The PAI-1 content of the thrombi increased significantly on augmentation of blood with isolated platelets, and reached levels comparable with those in human thrombi. These Chandler thrombi thus provide an appropriate model system for the study of thrombus lysis, in contrast to static blood clots.

• References

• 1 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
• 2 Declerck PJ, Alessi M-C, Verstreken MV, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
• 3 Kruithof EKO. Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2 (02) 59-70
• 4 Lang I, Schleef RR. Calciu-dependent stabilization of type 1 plasminogen activator inhibitor within platelet α-granules. J Biol Chem 1996; 271: 2754-2761
• 5 Kruithof EKO, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1: development of radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
• 6 Robbie LA, Booth NA, Croll AM, Bennett B. The roles of α₂-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-306
• 7 Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest 1989; 84: 647-655
• 8 Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem 1992; 267: 7128-7135
• 9 Levi M, Biemond BJ, van Zonneveld A-J, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor 1 (PAI-1) activity results in promotion of spontaneous thrombolysis and inhibition of hrombus growth in models of experimental thrombosis. Circulation 1992; 85: 305-312
• 10 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Reguation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: Light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299
• 11 Stringer HAR, van Swieten P, Heijnen FG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance: studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-1458
• 12 Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial type plasminogen activator inhibitor in human blood. Thromb Haemost 1986; 55: 325-329
• 13 Simpson AJ, Booth NA, Moore NR, Bennett B. The platelet and plasma pools of plasminogen activator inhibitor PAI-1 vary independently in disease. Br J Haematol 1990; 75: 543-548
• 14 Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62: 1083-1087
• 15 Kunitada S, Fitzgerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79: 1420-1427
• 16 Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor 1-dependent and -independent mechanisms. Blood 1994; 83: 351-356
• 17 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost 1981; 45: 225-229
• 18 Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749-1755
• 19 Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928
• 20 Robbie LA, Bennett B, Brown PAJ, Croll AM, Booth NA. Activators and inhibitors of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 5: 127-133
• 21 Legrand C, Dubemard V, Nurden AT. Characteristics of collagen-induced fibrinogen binding to human platelets. Biochim Biophys Acta 1985; 812: 802-810
• 22 Chandler AB. In vitro thrombotic coagulation of the blood. Lab Invest 1958; 7: 110-114
• 23 Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford A, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclo nal anti-alkaline phosphatase (APAAP complexes). JHistochem Cytochem 1984; 32: 219-229
• 24 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143
• 25 MacGregor IR, Tonner AM, Mickelm LR, James K, Booth NA. Murine monoclonal antibodies against active site epitopes on human endothelial plasminogen activator inhibitor (PAI-1). Fibrinolysis 1990; 4: 27-34
• 26 Tymkawycz PM, Creighton Kempsford LJ, Gaffney PJ. Generation and partial characterization of five monoclonal antibodies with high affinities for fibrin. Blood Coag Fib 1993; 4 (02) 211-221
• 27 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
• 28 Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB. The characterisation of thrombus development in an improved model of arteriovenous shunt thrombosis in the rat and the effects of recombinant desul- phatohirudin (CGP 39393), heparin and illoprost. Thromb Haemost 1991; 65: 268-274
• 29 Handt S, Jerome WG, Braaten JV, Lewis JC, Kirkpatrick CJ, Hantgan RR. PAI-1 released from cultured human endothelial cells delays fibrinolysis and is incorporated into the developing fibrin clot. Fibrinolysis 1994; 8: 104-112
• 30 Potter van Loon BJ, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex vivo lysibility. Thromb Haemost 1992; 67: 101-105
• 31 Declerck PJ, Lijnen HR, Verstreken M, Collen D. Role of α-AP in fibrin specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma. Thromb Haemost 1991; 65: 394-398